eFFECTOR(EFTR) - 2024 Q1 - Quarterly Results

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH and REDWOOD CITY, Calif., May 9, 2024 – eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treat ...